During his Senate confirmation hearings, Health Secretary Robert F. Kennedy Jr. suggested he wouldn’t undermine vaccines. “I ...

Findings showed mNexspike showed a 9.3% (99.4% CI, -6.6, 22.8) higher relative vaccine efficacy compared with Moderna’s original COVID-19 vaccine.

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to 64 years at high risk for severe disease, aligning with the agency ...

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it. It's not a replacement for the company’s existing shot, but a second option.

The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax ...